Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Eukaryotic Gene Expression
Импакт фактор: 1.841 5-летний Импакт фактор: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Печать: 1045-4403
ISSN Онлайн: 2162-6502

Выпуски:
Том 29, 2019 Том 28, 2018 Том 27, 2017 Том 26, 2016 Том 25, 2015 Том 24, 2014 Том 23, 2013 Том 22, 2012 Том 21, 2011 Том 20, 2010 Том 19, 2009 Том 18, 2008 Том 17, 2007 Том 16, 2006 Том 15, 2005 Том 14, 2004 Том 13, 2003 Том 12, 2002 Том 11, 2001 Том 10, 2000 Том 9, 1999 Том 8, 1998 Том 7, 1997 Том 6, 1996 Том 5, 1995 Том 4, 1994

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v8.i3-4.50
pages 321-356

The Development of Monoclonal Antibodies for the Therapy of Cancer

Roula A. Farah
The Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd., Dallas, Texas 75235-8576
Birgitta Clinchy
The Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd., Dallas, Texas 75235-8576
Larry Herrera
The Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd., Dallas, Texas 75235-8576
Ellen S. Vitetta
The Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd., Dallas, Texas 75235-8576

Краткое описание

Monoclonal antibodies (Mabs) were first decribed by Kohler and Milstein in 1975. Not only did this discovery lead to a Nobel prize, but it created an enormous scientific field that has now become a multimillion dollar industry. Mabs made the transition from laboratory reagents to clinical diagnostics very quickly. However, their development as therapeutic agents was, as predicted, more costly and time-consuming. Indeed, clinicians and scientists were required to learn a new set of rules for using these large, immunogenic, targeted agents in humans. Nevertheless, in 1997 the first Mab was licensed in the U.S. and several others will soon follow. In this review, we discuss Mab-based strategies for the treatment of cancer. We compare native, fragmented, recombinant and chimeric antibodies, bispecific antibodies, immunoconjugates, and immunoliposomes. The rationale for their development, their advantages, their in vitro and in vivo performance, and their clinical usefulness are discussed.


Articles with similar content:

Regulatory T-Cell Therapy in Transplantation and Severe Autoimmunity
Critical Reviews™ in Immunology, Vol.35, 2015, issue 6
Roberto Spreafico, Maura Rossetti
Adoptive Immunotherapy of Cancer Using Chimeric Antigen Receptor−Engineered T Cells
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 1-2
John Maher, Daniela Achkova
Early Historic Cancer Chemotherapy Work Involving Basidiomycetous Mushrooms
International Journal of Medicinal Mushrooms, Vol.1, 1999, issue 2
Paul A. Volz
Top-Down and Bottom-Up Approaches in 3D Printing Technologies for Drug Delivery Challenges
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 1
Babu Rao Chandu, Prakash Katakam, Baishakhi Dey, Nagiat Tayeb Hwisa, Shanta Kumari Adiki, Fathi H. Assaleh, Analava Mitra
Tumor-Stromal Interactions in Pancreatic Cancer
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 1 - 2
Daniel D. Von Hoff, Richard G. Posner, Haiyong Han, Clifford Whatcott